Thiruvengadam, S., Poh, C., Lynch, R., Moskowitz, C., Spinner, M., Hutchings, M., Herce, C. G., Phillips, E., Tun, A., Vose, J., Nayeri, M., Rudnicki, E., Delioukina, M., Fanale, M., Biswas, S., Lu, H., Visco, C. (2025). First-in-human, open-label, Phase 1 study of a novel CD30-directed antibody-drug conjugate with a topoisomerase 1 inhibitor payload, PF-08046044 (35C), in patients with Relapsed/Refractory lymphomas: Updated safety, PK, preliminary efficacy and ctdna analysis from dose escalation. Blood. https://doi.org/10.1182/blood-2025-155